PeptideInfo
Back to Directory

Tesamorelin

FDA Approved

Also known as: Egrifta, TH9507

Prescription Only — FDA Approved Medication

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

  • Growth Hormone Regulation
  • Fat Loss & Metabolism
  • Cognitive Enhancement
Mechanism of Action

Binds to pituitary GHRH receptors and stimulates endogenous GH secretion through the natural pulsatile feedback axis, increasing IGF-1 and reducing visceral adipose tissue in HIV-associated lipodystrophy. Research also examines GH-mediated effects on cognition through IGF-1 signaling in the brain.

Safety Notes

FDA-approved (Egrifta) for HIV-associated lipodystrophy. Side effects include injection site reactions, fluid retention, and carpal tunnel syndrome. May worsen insulin sensitivity.

Research Profile

Half-Life

~26 minutes

Administration

subcutaneous injection

Legal Status (US)

FDA-approved prescription medication for HIV-associated lipodystrophy. Off-label use requires prescription.

39 indexed research passages

Categories
Metabolic & Body CompositionGrowth & HormonalCognitive & Neurological
Research Interest Areas
Growth Hormone RegulationFat Loss & MetabolismCognitive Enhancement